×
Home Current Archive Editorial board
News Contact
Review paper

Cancer rate of Bethesda category II thyroid nodules

By
Francesk Mulita Orcid logo ,
Francesk Mulita
Contact Francesk Mulita

Department of General Surgery, University General Hospital of Patras, Patras, Greece

Fotios Iliopoulos ,
Fotios Iliopoulos

Department of General Surgery, University General Hospital of Patras, Patras, Greece

Christos Tsilivigkos ,
Christos Tsilivigkos

Department of General Surgery, University General Hospital of Patras, Patras, Greece

Levan Tchabashvili ,
Levan Tchabashvili

Department of General Surgery, University General Hospital of Patras, Patras, Greece

Elias Liolis ,
Elias Liolis

Department of Internal Medicine, University General Hospital of Patras, Patras, Greece

Charalampos Kaplanis ,
Charalampos Kaplanis

Department of General Surgery, University General Hospital of Patras, Patras, Greece

Ioannis Perdikaris ,
Ioannis Perdikaris

Department of General Surgery, University General Hospital of Patras, Patras, Greece

Ioannis Maroulis
Ioannis Maroulis

Department of General Surgery, University General Hospital of Patras, Patras, Greece

Abstract

Aim
Thyroid nodules are very common and may be found in more than 50% of the population. Fine-needle aspiration cytology
(FNAC) of thyroid nodules is a very useful diagnostic tool with high sensitivity and predictive value for diagnosis. The Bethesda System for Reporting Thyroid Cytopathology (BSRTC) uses six categories for thyroid cytology reporting (I-nondiagnostic, IIbenign, III-atypia of undetermined significance (AUS)/ follicular lesion of undetermined significance (FLUS), IV-follicular neoplasm/suspicious for follicular neoplasm (SFN), V-suspicious for malignancy, and VI-malignant. Our objective was to determine the malignancy rate in Bethesda II nodules.
Methods
From June 2010 to May 2020 a retrospective analysis was performed among 1166 patients who underwent thyroid surgery for benign thyroid diseases in our institution. Thyroid cytopathological slides and Ultrasound (US) reports were reviewed and classified according to the BSRTC. Data collected included age, gender, cytological features, and histological type of thyroid cancer.
Results
During the study period, 44.77% (522/1166) of patients with an FNA categorized as Bethesda II underwent thyroid surgery. Incidental malignancy was found in 1.53% (8/522) cases of Bethesda II. The most common malignant tumour type was papillary thyroid carcinoma.
Conclusion
The current study demonstrates that incidental thyroid carcinoma can be diagnosed after thyroidectomy even in patients
with an FNA categorized as Bethesda II.

References

1.
Mulita F, Plachouri M, Liolis E, Vailas M, Panagopoulos K, Maroulis I. Patient outcomes following surgical management of thyroid nodules classified as Bethesda category III (AUS/FLUS). Endokrynol Pol. 2021. p. 143–4.
2.
Popoveniuc G, Jonklaas J. Thyroid nodules. Med Clin North Am. 2012. p. 329–49.
3.
Thewjitcharoen Y, Butadej S, Nakasatien S, Chotwanvirat P, Porramatikul S, Krittiyawong S, et al. Incidence and malignancy rates classified by The Bethesda System for Reporting Thyroid Cytopathology (TBSRTC) -An 8-year tertiary center experience in Thailand. J Clin Transl Endocrinol. 2018. p. 100175.
4.
Richmond B, Judhan R, Chong B, Ubert A, Abu-Rahma Z, Mangano W, et al. False-negative results with the Bethesda System of reporting thyroid cytopathology: predictors of malignancy in thyroid nodules classified as benign by cytopathologic evaluation. Am Surg. 2014. p. 811–6.
5.
Flanagan M, Ohori N, Carty S, Hunt J. Repeat thyroid nodule fine-needle aspiration in patients with initial benign cytologic results. Am J Clin Pathol. 2006. p. 698–702.
6.
Cibas E, Ali S. The 2017 Bethesda System for Reporting Thyroid Cytopathology. Thyroid. 2017. p. 1341–6.
7.
Anand B, Ramdas A, Ambroise M, Kumar N. The Bethesda System for Reporting Thyroid Cytopathology: cytohistological study. J Thyroid Res. 2020. p. 8095378.
8.
Ha AH, Alqahtani R, Alahmadi A, Almutairi D, Algarni M, Alandejani T. Thyroid nodule size and prediction of cancer: a study at tertiary care hospital in Saudi Arabia. Cureus. 2020. p. 7478.
9.
Rossi E, Adeniran A, Faquin W. Pitfalls in thyroid cytopathology. Surg Pathol Clin. 2019. p. 865–81.
10.
Agcaoglu O, Aksakal N, Ozcinar B, Sarici I, Ercan G, Kucukyilmaz M, et al. Factors that affect the false-negative outcomes of fine-needle aspiration biopsy in thyroid nodules. Int J Endocrinol. 2013. p. 126084.
11.
Zhu Y, Song Y, Xu G, Fan Z, Ren W. Causes of misdiagnoses by thyroid fine-needle aspiration cytology (FNAC): our experience and a systematic review. Diagn Pathol. 2020. p. 1.
12.
Casella C, Ministrini S, Galani A, Mastriale F, Cappelli C, Portolani N. The New TNM staging system for thyroid cancer and the risk of disease downstaging. Front Endocrinol (Lausanne). 2018. p. 541.

Citation

Authors retain copyright. This work is licensed under a Creative Commons Attribution 4.0 International License. Creative Commons License

 

Article metrics

Google scholar: See link

The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.